Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Phasebio Pharmaceuticals Inc (PHAS)

Phasebio Pharmaceuticals Inc (PHAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 154,114
  • Shares Outstanding, K 28,699
  • Annual Sales, $ 670 K
  • Annual Income, $ -23,850 K
  • 60-Month Beta N/A
  • Price/Sales 220.40
  • Price/Cash Flow N/A
  • Price/Book 1.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.38
  • Low Estimate -0.41
  • Prior Year -10.45
  • Growth Rate Est. (year over year) +96.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.80 +11.88%
on 09/09/19
9.82 -45.34%
on 08/28/19
-2.39 (-30.80%)
since 08/13/19
3-Month
4.80 +11.88%
on 09/09/19
14.08 -61.86%
on 07/01/19
-6.61 (-55.18%)
since 06/13/19

Most Recent Stories

More News
Pharmacodynamics Evaluation of PhaseBio's Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that data...

PHAS : 5.37 (+4.68%)
PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that pharmacodynamic...

PHAS : 5.37 (+4.68%)
PhaseBio To Report Second Quarter 2019 Financial Results and Recent Corporate Progress on August 13, 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced it will...

PHAS : 5.37 (+4.68%)
PhaseBio Added to Russell 2000(R) and 3000(R) Indexes

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the...

PHAS : 5.37 (+4.68%)
PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced it will...

PHAS : 5.37 (+4.68%)
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the closing...

PHAS : 5.37 (+4.68%)
PhaseBio Announces Pricing of Public Offering of Common Stock

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the pricing...

PHAS : 5.37 (+4.68%)
Latest Biotechnology Advancements may be Key to Unlock new Autism Treatments

According to the Centers for Disease Control, autism affects an estimated 1 in 59 children in the United States today. The Autism Speaks website defines the main problem for researchers/practitioners...

QBIO : 0.8500 (-1.60%)
GERN : 1.59 (+0.63%)
INSM : 18.82 (-1.00%)
PHAS : 5.37 (+4.68%)
CMRX : 2.20 (+0.92%)
PhaseBio Announces Proposed Public Offering of Common Stock

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that it...

PHAS : 5.37 (+4.68%)
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

AZN : 42.77 (-0.30%)
ANIP : 76.53 (+5.59%)
KMDA : 5.26 (-0.38%)
PHAS : 5.37 (+4.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade PHAS with:

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

2nd Resistance Point 5.66
1st Resistance Point 5.51
Last Price 5.37
1st Support Level 5.15
2nd Support Level 4.94

See More

52-Week High 16.65
Fibonacci 61.8% 11.26
Fibonacci 50% 9.60
Fibonacci 38.2% 7.94
Last Price 5.37
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar